Bilayer fixed-dose combination tablet for curcumin microparticles and piroxicam and in vitroevaluation / Mayank Handa, Kamlesh Kumar, Debapriya Garabadu, Pramod Kumar Kushawaha, Rahul Shukla
Aim:In the present work, fixed-dose combination of bilayer tablets for piroxicam as and curcumin as immediate-release and sustained-release layer (SRL) respectively for management of inflammatory response.Materials & methods:The SRL include Curcumin polycaprolactone microparticles from spray drying. The tablet layers include Pearlitol 200SD, Microcrystalline cellulose PH101, Aerosil 200, talc each layer.Results:SEM studies confirm spherical microparticles. PXRD and DSC studies confirm the amorphous microparticles.In vitrostudies exhibit, an immediate release and sustained release for Piroxicam and Curcumin after 2 h. Cellular uptake studies on RAW 264.7 cells confirm the complete internalization of microparticles.Conclusion:Therefore, it was concluded that microparticles can be formulated into a unit dosage form for the management of inflammation. Aim: Materials & methods: Results: In vitro Conclusion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
Erscheinungsort nicht ermittelbar: 2023 |
| Enthalten in: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Handa, Mayank [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Bilayer tablet |
|---|
| Umfang: |
1 Online-Ressource (14 p) |
|---|
| doi: |
10.4155/tde-2022-0043 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011097620 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011097620 | ||
| 003 | DE-627 | ||
| 005 | 20230713210647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230609s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/tde-2022-0043 |2 doi | |
| 035 | |a (DE-627)KFL011097620 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/tde-2022-0043 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Handa, Mayank |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bilayer fixed-dose combination tablet for curcumin microparticles and piroxicam and in vitroevaluation |c Mayank Handa, Kamlesh Kumar, Debapriya Garabadu, Pramod Kumar Kushawaha, Rahul Shukla |
| 264 | 1 | |a [Erscheinungsort nicht ermittelbar] |c 2023 | |
| 300 | |a 1 Online-Ressource (14 p) | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim:In the present work, fixed-dose combination of bilayer tablets for piroxicam as and curcumin as immediate-release and sustained-release layer (SRL) respectively for management of inflammatory response.Materials & methods:The SRL include Curcumin polycaprolactone microparticles from spray drying. The tablet layers include Pearlitol 200SD, Microcrystalline cellulose PH101, Aerosil 200, talc each layer.Results:SEM studies confirm spherical microparticles. PXRD and DSC studies confirm the amorphous microparticles.In vitrostudies exhibit, an immediate release and sustained release for Piroxicam and Curcumin after 2 h. Cellular uptake studies on RAW 264.7 cells confirm the complete internalization of microparticles.Conclusion:Therefore, it was concluded that microparticles can be formulated into a unit dosage form for the management of inflammation. Aim: Materials & methods: Results: In vitro Conclusion | ||
| 653 | |a bilayer tablet | ||
| 653 | |a curcumin | ||
| 653 | |a fixed-dose combination | ||
| 653 | |a piroxicam | ||
| 653 | |a release | ||
| 653 | |a spray drying | ||
| 700 | 1 | |a Kumar, Kamlesh |e verfasserin |4 aut | |
| 700 | 1 | |a Garabadu, Debapriya |e verfasserin |4 aut | |
| 700 | 1 | |a Kushawaha, Pramod Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Shukla, Rahul |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Therapeutic Delivery |d London : Future Science, 2010 |h Online-Ressource |w (DE-627)KFL000006173 |w (DE-600)2590688-4 |w (DE-576)398101612 |x 2041-6008 |7 nnns |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/tde-2022-0043 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||